All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
The 2023 JSH practical guidelines for hematological malignancies: ALL
|
The 2023 JSH practical guidelines for hematological malignancies provide a treatment algorithm and recommendations for patients with ALL in Japan.1 These recommendations were published in the International Journal of Hematology by Hatta et al.1
|
| Key learnings |
| For patients with Ph+ ALL, TKI combined with chemotherapy is recommended, with allo-HSCT in first remission. In patients aged ≥65 years, TKI plus a steroid is recommended, with RIC and maintenance chemotherapy if possible. Preemptive TKI therapy is advised if MRD is detected post allo-HSCT; however, prophylactic TKI maintenance is not recommended if the patient is MRD-negative. TKI maintenance therapy for ≥5 years is recommended for patients not undergoing allo-HSCT in first remission. |
| For patients with Ph− ALL, pediatric-type chemotherapy is recommended for adolescents and young adults. For patients aged 40–64 years, high-dose methotrexate is recommended. Patients treated with pediatric-type protocols in first remission should continue chemotherapy, but allo-HSCT should be considered in patients with unfavorable prognostic factors. Standard therapy for patients aged ≥65 years is under development and current treatment options include combination chemotherapy or palliative steroid therapy tailored to individual patient needs. |
| MRD assessment after induction therapy is crucial. The optimal timing of subsequent MRD assessment varies depending on the treatment. Patients with MRD ≥0.01% after induction are at high risk of relapse and MRD monitoring should guide further treatment, including the timing of allo-HSCT. |
| For patients in remission, CNS prophylaxis with intrathecal anticancer drugs and either high-dose methotrexate or high-dose cytarabine is recommended for all adult patients. CNS prophylaxis with cranial irradiation is acceptable in high-risk patients. |
| For patients with R/R ALL undergoing reinduction therapy, prior treatments should be considered. Blinatumomab and inotuzumab ozogamicin are recommended for patients with CD19-positive and CD22-positive B-ALL, respectively. Later-generation TKIs can be considered in patients with Ph+ ALL who relapsed after earlier-generation TKIs. Nelarabine is a treatment option for patients with T-ALL. CAR T-cell therapy is an option for patients aged <25 years with CD19-positive B-ALL who did not achieve a second remission or relapsed after allo-HSCT. |
Abbreviations: ALL, acute lymphoblastic leukemia; allo-HSCT, allogeneic hematopoietic stem cell transplantation; B-ALL, B-cell ALL; CAR, chimeric antigen receptor; CNS, central nervous system; JSH, Japanese Society of Hematology; MRD, measurable residual disease; Ph, Philadelphia chromosome; R/R, relapsed/refractory; RIC, reduced-intensity conditioning; T-ALL, T-cell ALL; TKI, tyrosine kinase inhibitor.
- Hatta Y, Izutsu K, Onizuka M, et al. JSH practical guidelines for hematological malignancies, 2023: leukemia-3. Acute lymphoblastic leukemia/lymphoblastic lymphoma: ALL/LBL. Int J Hematol. 2024;120(4):394–413. DOI: 1007/s12185-024-03836-7
More about...
Your opinion matters
2 votes - 7 hours left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox